Companies / France
Ipsen And Medicis In US$194mn Deal
March 2006 | Company Finance AlertFrench pharmaceutical firm Ipsen has licensed its Reloxin (botulinum type A) anti-wrinkle drug to US-based Medicis
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.



